Also, it was demonstrated that 6HLN increases the SOD, GPX, and catalase (CAT) specific activities, reduces the MDA level, and increases the reduced glutathione (GSH) content in the hippocampal homogenates of SCOP- or CHL-treated rats, suggesting that 6HLN could be a potent compound with potential applications in AD therapy [191,192]. This evidence concerns the gene CAT and Alzheimer disease.